What's happening
This bill restores pharmacy benefits to managed care, sets new reimbursement rules for pharmacies, and ensures patient choice in prescription delivery.
Why it matters
Restores managed care pharmacy benefits and sets strict reimbursement rules. By requiring managed care plans and their pharmacy benefit managers (PBMs) to reimburse pharmacies at or above the National Average Drug Acquisition Cost (NADAC) plus a tiered dispensing fee (with a minimum set at $8.50), the bill directly impacts how much pharmacies are paid and may help ensure financial viability for smaller or independent pharmacies.
Enhances pharmacy network access and patient choice. The bill prohibits managed care providers and PBMs from excluding pharmacies willing to accept established reimbursement rates and from limiting patient access to their pharmacy of choice for prescription delivery, including local and mail options. This could help maintain a diverse network of pharmacies and support patient convenience and continuity of care.
Protects 340B program and community health providers. It mandates fair, transparent reimbursement and fee structures for 340B-covered entities and their contract pharmacies, moving away from percentage-based fees and toward fair market value, which may better support safety-net providers serving vulnerable populations.
Standardizes drug formularies to maximize rebates and reduce confusion. By requiring managed care plans to use the state’s preferred drug list, the bill aims to simplify the prescribing process for providers and patients, potentially increase state drug rebate revenues, and ensure more consistent access to medications across the Medicaid program.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Protect Local Pharmacy Access
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Restore Managed Care Pharmacy
In Assembly Committee · Health · Sponsor Amy Paulin
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
5136
2023-2024 Regular Sessions
IN SENATE
February 23, 2023
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the social services law and the public health law, in relation to pharmacy services provided by managed care providers and to repeal sections 1 and 1-a of part FFF of chapter 56 of the laws of
2020 relating to directing the department of health to remove the pharmacy benefit from the managed care benefit package and to provide the pharmacy benefit under the fee for service program, in relation thereto
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Sections 1 and 1-a of part FFF of chapter 56 of the laws of 2020 relating to directing the department of health to remove the pharmacy benefit from the managed care benefit package and to provide the pharmacy benefit under the fee for service program, are REPEALED.
§ 2. Subdivision 4 of section 364-j of the social services law is amended by adding four new paragraphs (x), (y), (z) and (aa) to read as follows:
(x) Notwithstanding any provision of law to the contrary, managed care providers under the medical assistance program and any pharmacy benefit managers acting on their behalf, as defined in section two hundred eighty-a of the public health law, shall be required to reimburse retail pharmacies for each outpatient drug, at the National Average Drug Acquisition Cost (NADAC), or if NADAC pricing is unavailable for a drug, reimbursement shall be pursuant to the current benchmarks under fee-forservice, plus a tiered professional dispensing fee based on prescription claims volume to be determined by the commissioner. In determining a professional dispensing fee, the commissioner shall issue a survey that collects claims volumes from enrolled pharmacies, and other such information as the commissioner may deem necessary to weigh regional variances and other factors significantly impacting markets from the previ-
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD09373-03-3
ous twelve-month period, to determine the appropriate dispensing fee reimbursement. The dispensing fee determined by the commissioner shall be in an amount of at least eight dollars and fifty cents.
(y) (i) Notwithstanding any provision of law to the contrary, a managed care provider or pharmacy benefit manager acting on its behalf, shall not deny any retail pharmacy the opportunity to participate in another provider's pharmacy network under the medical assistance program, provided that:
(A) such retail pharmacy agrees to the same reimbursement amount;
(B) is able to fill and dispense commonly dispensed prescriptions and over-the-counter medications in a manner consistent with medical assistance program guidance and statute for those patients and population the pharmacy serves enrolled in the medical assistance program;
(ii) Nothing in this paragraph shall require a managed care provider or pharmacy benefit manager to contract with a retail pharmacy or pharmacies that fail to meet universally accepted professional standards of pharmacy practice. Further, nothing in this paragraph shall be construed as limiting the ability of managed care providers or pharmacy benefit managers to remove pharmacies from their network, or to decline to contract with pharmacies in cases of fraud, waste, abuse, or as otherwise authorized by law.
(z) (i) A managed care provider or pharmacy benefit manager acting on its behalf shall be required to reimburse 340B covered entity providers, whether directly or through arrangements with their contractual pharmacies, for outpatient drugs dispensed under section 340B of the federal public health service act (42 USCA § 256b), at NADAC, or if NADAC pricing is unavailable for a drug, reimbursement shall be pursuant to the current benchmarks under fee-for-service, plus a professional dispensing fee as determined by the commissioner pursuant to paragraph (x) of this subdivision.
(ii) Notwithstanding any provision of law to the contrary, rates of payment between covered entities under section 340B of the public health service act and contract pharmacies that obtain and dispense 340B drugs on behalf of the covered entity, shall comprise a fee schedule, based on fair market value principles and shall not be a percentage of either the claim's total reimbursement or net margin. The commissioner shall evaluate the adequacy of such fee schedule no less than every two years.
(aa) Notwithstanding any provision of law to the contrary, in order to align managed care provider drug formularies to reduce complexity for beneficiaries of medical assistance, and to maximize available federal statutory drug rebates for the state, managed care providers and any pharmacy benefit managers acting on their behalf, shall be required to use the fee-for-service preferred drug list when developing a formulary or preferred drug list of outpatients drugs for beneficiaries of medical assistance. In the interests of the creation of a high quality uniform formulary, and notwithstanding any provision of law to the contrary: the commissioner shall convene a committee comprised of the pharmacy directors of the state's currently participating managed care providers to advise in the creation and stewardship of any such formulary or preferred drug list.
§ 3. Section 280-a of the public health law is amended by adding a new subdivision 6 to read as follows:
6. Medical assistance delivery option. Notwithstanding any provision of law to the contrary, no pharmacy benefit manager shall limit the option for an individual exercising their benefits under the state's medical assistance program receiving prescription or over-the-counter medications to receive such medications from their local, non-mail order pharmacy of choice via delivery including in-person delivery, United States postal service or other mail or courier service. No restrictions, prohibitions, or prior authorization requirements shall be based on the individual's choice in delivery type or distance from a pharmacy.
§ 4. This act shall take effect immediately; provided, however, that sections two and three of this act shall be deemed to have been in full force and effect on and after April 1, 2023.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the social services law and the public health law, in relation to pharmacy services provided by managed care providers and to repeal sections 1 and 1-a of part FFF of chapter 56 of the laws of 2020 relating to directing the department of health to remove the pharmacy benefit from the managed care benefit package and to provide the pharma- cy benefit under the fee for service program, in relation thereto
Purpose or general idea of bill
The purpose of this bill is to repeal the transition of the Medicaid pharmacy benefit from managed care to fee-for-service, which would cause unintentional harm to certain providers participating in the federal 340B program, while still maintaining protections for pharmacy oper- ations and reducing administrative costs associated with the 340B program.
Summary of specific provisions
Section 1 of the bill would repeal Sections 1 and 1-a of part FFF of chapter 56 of the laws of 2020 that authorizes the Department of Health (DOH) to transition the pharmacy benefit from managed care into fee-for- service.
Read the full memo (683 words)
Section 2 of the bill requires all managed care providers and pharmacy benefit managers to use the feefor-service preferred drug list in devel- oping their formulary. All managed care organizations and pharmacy bene- fit managers would be required to reimburse retail pharmacies and 340B covered entity providers for each drug at the National Average Drug Acquisition Cost (NADAC) plus a tiered volume-based dispensing fee to be determined by DOH. If a specific drug does not have a NADAC rate, then feefor-service reimbursement methodologies would be used. The bill requires the dispensing fee set by the Commissioner of DOH to be an amount of at least $8.50, but would allow for it to be increased above this amount for smaller pharmacies dispensing lower volumes that may be subject to higher operational costs. Managed care providers would be prohibited from denying retail pharmacies the opportunity to participate in their network under Medicaid under certain conditions. Contract phar- macies performing services under the 340B program would be reimbursed under a fee schedule that is based on fair market principles and cannot be a percentage of a claim's total reimbursement or net margin.
Section 3 would prohibit pharmacy benefit managers from limiting an individual's choice to receive their medication form their local, non- mail order pharmacy of choice.
Section 4 is the effective date.
Justification
The SFY 2020-21 final adopted budget included a provision that transi- tions the Medicaid pharmacy benefit from managed care to the fee-for- service program. While the implementation of the transition was delayed for two years in the SFY 2021-22 budget, the transition is now set to go forward on April 1, 2023. The transition eliminates the ability of safety-net providers to utilize savings from the federal 340B program, as that program can only operate under managed care and not fee-for-ser- vice. The 340B drug rebate program provides funding to safety-net providers that is used to expand healthcare services and other programs for vulnerable, high-need populations. Some estimates show that safety- net providers will lose hundreds of millions of dollars from lost 340B funding.
This bill maintains the pharmacy benefit within managed care, which preserves the 340B drug rebate mechanism. Instead, a single Preferred Drug List (PDL) would be created that would require uniform utilization review management protocols, enhance the State's negotiating power for drug rebates, and provide greater transparency in the program. The bill will also end restrictive and anti-competitive pharmacy benefit manager (PBM) practices by protecting pharmacy networks, limiting fees that PBM's and other third-party middlemen siphon from the program, and phar- macists will receive a fair and transparent dispensing fee.
This bill achieves many of the same goals of the original carveout, but with much less disruption to important safety-net providers across the state.
Prior legislative history
New bill.
Fiscal implications
Undetermined, but potential savings to the Medicaid program from effi- ciencies in the single formulary.
Effective date
This act shall take effect immediately; except that sections two and three shall take effect April 1, 2023.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.